PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Wednesday that it has filed a provisional application at the Australian Patent Office with the aim of seeking protection for certain peptides analogues of dynorphin and their use in pain management.
"Building a library of intellectual properties and having these protected is our Company's strategy,” PreveCeutical CEO Stephen Van Deventer said in a statement.
“The provisional application filing for peptide IP will add tremendous value and building partnerships for commercialization of peptide-based therapies."
READ: PreveCeutical says cannabinoid Sol-gel formulations showed physical and chemical stability in study
PreveCeutical has been advancing its non-addictive analgesic peptide program to replace highly addictive drugs such as morphine, fentanyl and oxycodone. It is also being studied as a therapeutic product for treating athletes suffering from concussions.
The company recently completed a preclinical study of a dynorphin pain peptide on rats that “demonstrated effectiveness in alleviating moderate inflammatory pain” after administration of a single dose. Researchers plan to test other shortlisted peptides in an in-vivo rat model.
Vancouver-based PreveCeutical is also seeing encouraging preliminary results from its research and development program which is expected to enable the company to generate key peptide therapeutics for use in the treatment of brain cancer.
Preliminary screening in an aggressive brain cancer assay successfully identified four lead peptides that inhibit the activity of a target protein found in the progression in certain glioblastomas.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham